Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Effecten van granaatappelsap op colitis ulcerosa

16 november 2026 bijgewerkt door: Zhaoping Li, University of California, Los Angeles

Effect van granaatappelsap op darmontsteking, kwaliteit van leven en het darmmicrobioom bij patiënten met colitis ulcerosa: een pilotstudie

The purpose of this study is to determine whether consumption of 237 ml of pomegranate juice daily for 8 weeks will:

  1. lower inflammation (in the gut as well as generally in the body) and improve your overall quality of life
  2. affect the microbes living in the gut (gut microbiota)

Studie Overzicht

Gedetailleerde beschrijving

the study is aimed at evaluating the effects of pomegranate juice (PomJ) on: 1) gut inflammation (fecal calprotectin and Simple Clinical Colitis Activity Index) and quality of life; 2) circulating inflammatory markers (e.g., hs-CRP, IL-6, IL-10, TNF-a, IL-1b, IL-8, LBP, LPS) and markers of oxidative stress (blood and urine malondialdehyde (MDA)) and 3) gut microbiota composition and functionality (urinary and circulating urolithin metabolites, fecal SCFAs/BAs, blood LBP and LPS, etc.). We will perform a randomized, controlled, 16-week trial to generate preliminary evidence on the effects of PomJ consumption in patients with mild-to-moderate UC. Participants will be randomly assigned to one of two groups: intervention group and delayed start group. The study will involve 2 phases, each lasting for 8 weeks. During Phase 1, the intervention group will consume 237 ml of PomJ daily, while the delayed start group will follow their habitual diet. Data generated from the delayed start group during Phase 1 will serve as the control for the study. During Phase 2, the intervention group will stop consuming PomJ and switch to consuming their habitual diet, while the delayed start group will consume 237 ml of PomJ daily for 8 weeks. Data generated from the intervention group during Phase 2 will serve as a follow-up to explore whether the effects of PomJ consumption persist after consumption is stopped (this will be an exploratory outcome).

Studietype

Ingrijpend

Inschrijving (Geschat)

30

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Locaties

    • California
      • Los Angeles, California, Verenigde Staten, 90073
        • Nog niet aan het werven
        • West Los Angeles VA Medical Center
        • Hoofdonderzoeker:
          • Zhaoping Li, MD, PhD
        • Contact:
      • Los Angeles, California, Verenigde Staten, 90095
        • Werving
        • UCLA Center for Human Nutrition
        • Hoofdonderzoeker:
          • Zhaoping Li, MD, PhD
        • Contact:
        • Onderonderzoeker:
          • Berkeley Limketkai, MD, PhD

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • • Adults ≥ 18 yo

    • Following a low-polyphenol and fiber diet (< 3 servings of fruits/vegetables per day)
    • Mild-to-moderate UC at the time of screening (2 ≤ partial Mayo scores ≤ 5)
    • Supportive evidence of active inflammation (hsCRP >1 mg/L, fecal calprotectin >50 µg/g stool, or abnormal lower endoscopy) in individuals with biopsy-proven UC
    • Patients on 5-aminosalicylates must be on a stable dose for ≥ 4 weeks prior to screening
    • Patients on treatment with immunosuppressive therapy (e.g., azathioprine/6-mercaptopurine, methotrexate) must be on stable dose for 8 weeks prior to baseline visit
    • At the time of baseline visit, patients may be on no more than 20 mg/day of prednisone and 9 mg/day of budesonide MMX
    • Subjects must read and sign the Institutional Review Board-approved written informed consent prior to the initiation of any study specific procedures or enrollment. A subject will be excluded for any condition that might compromise the ability to give truly informed consent.

Exclusion Criteria:

  • • Non-English speaker

    • Vegetarian/vegan
    • Known pomegranate allergy
    • Documented chronic disease besides UC, including diabetes, renal or liver diseases, metabolic syndrome, active cancer, MI or stroke, history of gastric bypass
    • Patients with CD, indeterminate/severe to fulminant colitis
    • History of colectomy or colonic dysplasia
    • Presence of ileal pouch or ostomy
    • Evidence of active bacterial or viral gastroenteritis as indicated by positive stool studies for ova & parasites, Clostridium difficile, and stool culture
    • Recent hospitalizations (within 2 weeks of screening) for UC requiring IV steroids
    • Presence of the following labs indicative of severe colitis: a. Hemoglobin < 8.0 g/dl b. Albumin < 3.0 g/dl
    • Recent systemic antibiotics use (within 3 months of screening) or active use of anti-diarrheal medications
    • Taking supplements known to affect metabolism or gut microbiota composition (probiotics, fiber, etc.), unless willing to stop for the study duration
    • Use of Total Parenteral Nutrition (TPN)
    • Use of cyclosporine, tacrolimus, or thalidomide within 2 months prior to screening
    • Taking exogenous hormones (e.g., hormone replacement therapy)
    • Recent weight fluctuations (>10% in the last 6 months)
    • Smoker or living with a smoker
    • Use of >20 g of alcohol per day
    • Unable or unwilling to comply with the study protocol (including unwillingness to avoid watermelon and other lycopene-rich foods for the whole duration of the study)
    • Unable to provide consent

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Ondersteunende zorg
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Crossover-opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Intervention

Participants in this arm will be consuming 237 ml of pomegranate juice for the first 8 weeks of the study and their habitual diet without pomegranate juice for the second 8 weeks

237 ml of pomegranate juice for the first 8 weeks -> habitual diet for the second 8 weeks

Experimenteel: Delayed start

Participants in this arm will consume their habitual diet for the first 8 weeks of the study and drink 237 ml of pomegranate juice for the second 8 weeks

habitual diet for the first 8 weeks -> 237 ml of pomegranate juice for the second 8 weeks

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
simple clinical colitis activity index (SCCAI)
Tijdsspanne: At baseline, 8 weeks and 16 weeks

Simple Clinical Colitis Activity Index (SCCAI) includes questions about bowel frequency, urgency of defecation, etc. Measured by the number of points/scores.

At baseline, 8 weeks and 16 weeks
Fecal calprotectin
Tijdsspanne: At baseline, 8 weeks and 16 weeks

To evaluate effects of PomJ on gut inflammation in patients with mild-to-moderate UC. The primary outcome will be levels of fecal calprotectin (objective measure). Fecal calprotectin levels will be assessed via a commercially available ELISA kit in mcg/g.

At baseline, 8 weeks and 16 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, week 8 and week 16

Blood interleukin-6 (IL-6) in pg/ml

At baseline, week 8 and week 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, week 8 and week 16

Blood interleukin-10 (IL-10) in pg/ml

At baseline, week 8 and week 16
Biomarkers of aging and oxidative stress
Tijdsspanne: At baseline, week 8 and week 16

Blood TNF-a in pg/ml

At baseline, week 8 and week 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, week 8 and 16

Blood IL-1b in pg/ml

At baseline, week 8 and 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16

Blood IL-8 in pg/ml

At baseline, weeks 8 and 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At Baseline, weeks 8 and 16

Blood hs-CRP in mg/ml

At Baseline, weeks 8 and 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16

Urine malondialdehyde (MDA) in ng/ml

At baseline, weeks 8 and 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16

Blood MDA in nmol/ml

At baseline, weeks 8 and 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16

Urine 8OHdG in ng/mg

At baseline, weeks 8 and 16
Biomarkers of inflammation and oxidative stress
Tijdsspanne: At baseline, weeks 8 and 16

Blood 8OHdG in ng/ml

At baseline, weeks 8 and 16

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Gut-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16

Blood urolithin metabolites in micromoles/L

At baseline, weeks 8 and 16
Gut-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16

Urine urolithin metabolites

At baseline, weeks 8 and 16
Microbial inflammatory components
Tijdsspanne: At baseline, weeks 8 and 16

Blood lipopolysaccharide in ng/ml

At baseline, weeks 8 and 16
Microbial inflammatory components
Tijdsspanne: At baseline, weeks 8 and 16

Blood LPS binding protein in micrograms/ml

At baseline, weeks 8 and 16
Microbial-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16

Fecal short-chain fatty acids (SCFAs) in micromoles/g

At baseline, weeks 8 and 16
Microbial-derived metabolites
Tijdsspanne: At baseline, weeks 8 and 16

Fecal bile acids (BAs) in ng/ml

At baseline, weeks 8 and 16
Gut microbiota composition
Tijdsspanne: At baseline, weeks 8 and 16

The stool specimen will be collected by the participants at home at baseline and week 12 utilizing our Stool Collection Kit as per instructions. Immediately after collection, the specimen will be frozen in a home freezer and delivered in an insulated container to the UCLA Center for Human Nutrition. At UCLA, the specimen will be stored at - 80 ºC. Fecal microbiological analyses. Approximately 1g of the stool will be weighed and dried in a vacuum drying oven (15 in Hg) at 80 ºC for 48 hours, then weighed again to establish the moisture content so that all counts can be corrected to dry weight. From another aliquot of remaining fecal samples, DNA will be extracted using bead beating with a commercial extraction system (DNeasy PowerSoil® DNA Isolation Kit, Qiagen, Valencia, CA). The quality of the DNA samples will be confirmed using a Nanodrop 1000 (Thermo Fisher Scientific, Wilmington, DE). Extracted DNA will be transferred to UCLA Microbiome Core facility for MiSeq sequencing.

At baseline, weeks 8 and 16

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Onderzoekers

  • Hoofdonderzoeker: Zhaoping Li, MD, PhD, University of California, Los Angeles

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

15 oktober 2025

Primaire voltooiing (Geschat)

15 oktober 2027

Studie voltooiing (Geschat)

15 oktober 2027

Studieregistratiedata

Eerst ingediend

4 augustus 2025

Eerst ingediend dat voldeed aan de QC-criteria

4 augustus 2025

Eerst geplaatst (Werkelijk)

11 augustus 2025

Updates van studierecords

Laatste update geplaatst (Werkelijk)

18 november 2026

Laatste update ingediend die voldeed aan QC-criteria

16 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Andere studie-ID-nummers

  • IRB-25-1553
  • T32DK007180 (Subsidie/contract van de Amerikaanse NIH)

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Beschrijving IPD-plan

Data analysis will be performed in-house.

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren